Melice

Meloxicam, the active ingredient in Melice, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It is used to relieve pain and inflammation associated with osteoarthritis, rheumatoid arthritis and other musculoskeletal conditions in adult patients. GNH USA supplies Melice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is an NSAID that targets inflammatory pathways in musculoskeletal disorders. - Osteoarthritis: reduces joint pain and improves mobility. - Rheumatoid arthritis: decreases synovial inflammation and joint swelling. - Acute pain: provides rapid relief of moderate to severe pain. - Inflammatory arthritis: limits disease‑related stiffness and swelling.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Gastrointestinal discomfort such as dyspepsia or nausea. - Headache or dizziness. - Mild skin rash or pruritus. - Peripheral edema.

Serious or Rare Side Effects: - Peptic ulcer disease or gastrointestinal bleeding. - Severe hypersensitivity reactions including Stevens‑Johnson syndrome. - Renal impairment or sudden loss of kidney function.

Before prescribing Melice, consider the following safety measures. - Cardiovascular risk: avoid in patients with a history of myocardial infarction or uncontrolled hypertension. - Gastrointestinal risk: use cautiously in individuals with prior ulcer disease or chronic NSAID use. - Renal function: monitor serum creatinine in patients with existing kidney disease. - Hepatic impairment: adjust use if liver enzymes are elevated. - Pregnancy and lactation: only use if the potential benefit justifies the potential risk. - Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Meloxicam can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of serious bleeding. - Other NSAIDs or COX‑2 inhibitors: heightened gastrointestinal toxicity. - Lithium: may raise serum lithium levels.

Moderate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible reduction in renal function. - Diuretics: may potentiate renal adverse effects. - Methotrexate: potential for increased toxicity at high doses.